Cutler Group LP Corvus Pharmaceuticals, Inc. Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.87 - $2.03 $4,089 - $9,540	-4,700 Closed	0 $0
Q1 2022 Apr 14, 2022	SELL	$1.46 - $2.48 $1,458 - $2,477	-999 Reduced 17.53%	4,700 $7,000
Q4 2021 Jan 18, 2022	SELL	$2.34 - $5.31 $23,402 - $53,105	-10,001 Reduced 63.7%	5,699 $13,000
Q3 2021 Oct 26, 2021	BUY	$1.89 - $8.53 $28,161 - $127,096	14,900 Added 1862.5%	15,700 $75,000
Q1 2021 Apr 26, 2021	SELL	$2.86 - $4.77 $572 - $953	-200 Reduced 20.0%	800 $2,000
Q4 2020 Jan 21, 2021	SELL	$3.56 - $4.86 $1,068 - $1,458	-300 Reduced 23.08%	1,000 $3,000
Q3 2020 Oct 27, 2020	BUY	$2.6 - $5.37 $3,380 - $6,981	1,300 New	1,300 $5,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.